This technology is based on the discovery of the interaction between Reelin and the VLDL receptor. It provides a convenient assay system for receptor binding that is adaptable for screening modulators of the interaction between Reelin and the VLDL receptor or similar receptors. Reelin-signaling underlies the apparent “spread” of the neuropathology across brain networks in patients diagnosed with Alzheimer’s (AD), and could aid in early diagnosis.
Reelin, VLDL receptor, Alzheimer’s, Neurodegenerative diseases
Granted Patents or Published Applications
U.S. Patent No. 6,323,177
Related Scientific References
D. Krstic, S. Pfister, T. Notter, I. Knuesel, “Decisive role of Reelin signaling during early stages of Alzheimer’s disease”, Neuroscience 246:108-116 (2013);
D'Arcangelo G, et al., “Reelin is a ligand for lipoprotein receptors”, Neuron 24(2):471-9 (1999).
We are currently seeking licensing opportunities in all fields for the development of this technology.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.